Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

PURPOSE: Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. PATIENTS AND METHODS: This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the intravenously administered, highly selective EZH2 inhibitor, GSK2816126, (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Yap, Timothy A., Winter, Jane N., Giulino-Roth, Lisa, Longley, Jemma, Lopez, Juanita, Michot, Jean-Marie, Leonard, John P., Ribrag, Vincent, McCabe, Michael T., Creasy, Caretha L., Stern, Melissa, Pene Dumitrescu, Teodora, Wang, Xiaowei, Frey, Steve, Carver, Jennifer, Horner, Thierry, Oh, Choon, Khaled, Ahmed, Dhar, Arindam, Johnson, Peter W.M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7377921/
https://ncbi.nlm.nih.gov/pubmed/31471312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-4121
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky